MCLICK: Empowering Mono & Dual Payload AXC Innovation via a Pure Chemo Approach - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

MCLICK: Empowering Mono & Dual Payload AXC Innovation via a Pure Chemo Approach

12:30 pm - Wednesday 14th October 2026

Achieving highly selective reduction of inter-chain S-S bonds in IgG1
Leveraging MCLICK to enable AXC with various DARs and ratios
Empowering AXC innovation with MCLICK and other platforms

Speakers:

Ao Ji

Ao Ji

Chief Scientific Officer

Bio-Reinnovation